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Abstract
Background: Cancer is a complex disease where various types of molecular aberrations drive the development
and progression of malignancies. Large-scale screenings of multiple types of molecular aberrations (e.g., mutations,
copy number variations, DNA methylations, gene expressions) become increasingly important in the prognosis and
study of cancer. Consequently, a computational model integrating multiple types of information is essential for the
analysis of the comprehensive data.
Results: We propose an integrated modeling framework to identify the statistical and putative causal relations of
various molecular aberrations and gene expressions in cancer. To reduce spurious associations among the massive
number of probed features, we sequentially applied three layers of logistic regression models with increasing
complexity and uncertainty regarding the possible mechanisms connecting molecular aberrations and gene
expressions. Layer 1 models associate gene expressions with the molecular aberrations on the same loci. Layer 2
models associate expressions with the aberrations on different loci but have known mechanistic links. Layer 3
models associate expressions with nonlocal aberrations which have unknown mechanistic links. We applied the
layered models to the integrated datasets of NCI-60 cancer cell lines and validated the results with large-scale
statistical analysis. Furthermore, we discovered/reaffirmed the following prominent links: (1)Protein expressions are
generally consistent with mRNA expressions. (2)Several gene expressions are modulated by composite local
aberrations. For instance, CDKN2A expressions are repressed by either frame-shift mutations or DNA methylations.
(3)Amplification of chromosome 6q in leukemia elevates the expression of MYB, and the downstream targets of
MYB on other chromosomes are up-regulated accordingly. (4)Amplification of chromosome 3p and hypo-
methylation of PAX3 together elevate MITF expression in melanoma, which up-regulates the downstream targets
of MITF. (5)Mutations of TP53 are negatively associated with its direct target genes.
Conclusions: The analysis results on NCI-60 data justify the utility of the layered models for the incoming flow of
cancer genomic data. Experimental validations on selected prominent links and application of the layered
modeling framework to other integrated datasets will be carried out subsequently.
Background
Cancer is a systemic disease where alterations of various
physiological processes drive the development and pro-
gression of malignancies (e.g., [1-5]). These alterations
result from combinations of many cytogenetic/molecular
aberrations such as large-scale karyotype changes (e.g.,
[6]), sequence alterations onp r o t e i n - c o d i n go rr e g u l a -
tory regions (e.g., [7,9]), DNA copy number variations
(e.g., [10]), epigenetic modification changes (e.g., [5,11]),
alterations of mRNA (e.g., [12]), protein (e.g., [13]) and
microRNA (e.g., [14]) expressions. A comprehensive
characterization of a cancer system requires concurrent
measurements of these diverse molecular aberrations in
the same set of samples. Several international consortia
and research institutions have launched large-scale pro-
jects to catalog the genomic, transcriptomic and epige-
nomic changes across multiple tumor types and
generated preliminary data (e.g., [7,15,16]). In addition,
comprehensive assays on the NCI-60 cancer cell lines
have been performed by distinct research groups over
the last two decades (e.g., [6,9,17-22,13,23]).
As the large-scale, comprehensive assays will be com-
mon in cancer research and prognosis, it is essential to
perform integrative computational analysis of the Correspondence: chyeang@webmail.stat.sinica.edu.tw
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understanding of the underlying biology. Currently inte-
grative analyses of cancer data focus on three interre-
lated directions. First, molecular biomarkers identified
from each type of data were combined to improve the
prognostic accuracy of tumors. Meta-analysis is typically
applied to multiple datasets in tumor classification and
prediction (e.g., [24-26]). Second, beyond single markers
most recent studies examined the abnormal pathway
activities by combining the molecular aberrations of
their constituent genes (e.g., [12,15,16,27-29]). Third,
some studies also tracked the causes of abnormal gene
expressions by correlating them with DNA copy num-
bers, gene mutations, DNA methylations or microRNA
expressions (e.g., [16,30-33]). Beyond cancer data various
computational models of data integration have been
applied to other datasets. Examples include probabilistic
Bayesian models [34], probabilistic relational models
[35], mutual information networks [36], module net-
works [37] and factor graphs ([38,39]).
Despite the rich literature of data integration in com-
putational biology, several issues have not been widely
addressed in cancer data analysis. First, most integrative
cancer studies tend to apply case-by-case analysis to
combine different types of data. For instance, a common
method of integrating copy number and gene expression
data is to calculate the correlation coefficients between
DNA copy numbers and mRNA expressions of the same
genes (e.g., [17,30]). This analysis only captures simple,
pairwise relations of molecular aberrations and is diffi-
cult to extend to a wide variety of data. A coherent fra-
mework that unifies distinct types of molecular data in
the same model is needed. While such probabilistic
models have been applied to other organisms and the
clinical data of human diseases, they have not been
widely applied to the comprehensive molecular aberra-
tion data of cancer. Second, tracing the statistical and
causal relations of multiple molecular aberrations is
important for understanding the mechanisms of cancer
phenotypes but is not emphasized in existing studies of
cancer data integration. Pairwise correlations fail to dis-
tinguish between direct and indirect effects of molecular
aberrations and cannot capture the combinatorial rela-
tions of multiple aberrations. For instance, the mRNA
expression of a gene can be elevated by the amplifica-
tion of its DNA copies or by the amplification of its
transcription factor. A general statistical model that
delineates the direct, indirect effects and combinatorial
interactions is required. Third, genome-wide associa-
tions on heterogeneous data suffer from the curse of
dimensionality as the number of probed features far
exceeds the sample size. Various statistical techniques
are proposed to alleviate the small-sample problem by
controlling model complexity or assessing the reliability
of multi-hypotheses tests (e.g., [40-42]). However, the
association results are often difficult to interpret in
terms of mechanisms. Some associations can be attribu-
ted to known molecular mechanisms (e.g., the frame-
shift insertion/deletion of a gene disrupts its mRNA
synthesis), while other associations may have unknown
mechanistic links (e.g., a MAP kinase activates a gene
expression via an unknown signaling pathway). These
mechanistic information should be utilized to assign the
confidence of associations and to identify the novel links
not explained by known mechanisms.
In this study, we propose a layered modeling frame-
work to tackle these issues. The goal of the model is to
explain the molecular phenotypes - mRNA and protein
expressions - with the observed molecular aberrations.
Associations with phenotypes are classified into three
layers according to the level of uncertainty and com-
plexity for their mechanistic interpretations. Layer 1
models associate gene expressions with the molecular
aberrations on the same loci. Layer 2 models associate
the expressions with the aberrations on different loci
but have known mechanistic links. Layer 3 models
associate the expressions with nonlocal aberrations
which have unknown mechanistic links. We sequentially
incorporate the associations belonging to increasing
layers to fit the phenotype data. Each layer of models
are formulated by logistic regression models of multiple
variables, and new variables that provide additional
explanatory powers are included according to a nested
hypothesis testing procedure. We applied the layered
models to the integrated datasets of NCI-60 cell lines
and discovered/reaffirmed prominent mechanistic links
pertaining to major oncogenes and tumor suppressors
including CDKN2A, TP53, MYB, MITF, PAX3, and
other genes.
Methods
Overview of the integrated modeling framework
The goal of this work is to find the molecular aberra-
tions that explain the variations of gene expressions
across a panel of cancer and/or normal samples. We use
logistic regressions to model the dependency of molecu-
lar aberrations and gene expressions for their simplicity
and expressiveness for the effects of multiple inputs.
Features (variables) are sequentially incorporated in the
model based on statistical hypothesis tests. A new vari-
able is added to an existing model if the joint model sig-
nificantly outperforms both the existing model and the
model with the new variable alone. To preserve the
information of continuous data (e.g., mRNA expres-
sions) we applied probabilistic quantization to convert
intensities (e.g., log ratios in the mRNA expression data)
into probabilities of each state (e.g., up/down regulation
or no change). Probabilistic quantization, logistic
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described in subsequent sections of Methods and Addi-
tional file 1 (Section Data processing).
The novelty of our approach dwells on the priority of
incorporating molecular aberrations in the model. We
propose a layered modeling framework to identify the
molecular aberrations explicating the expression data.
The central idea is to sequentially apply a hierarchy of
models with increasing complexity and uncertainty
regarding the possible mechanisms connecting molecu-
lar aberrations and gene expressions. A more complex
model is not incorporated unless either the aberration
data required for simpler models are not available or the
explanatory power of the former significantly surpasses
the power of any simpler models. We classify the
mechanistic models into three layers according to the
directness and uncertainty connecting the causes
(observed molecular aberrations) and effects (observed
gene expressions). Figure 1 illustrates the relations of
molecular aberrations in each class.
1. Layer 1 models: Local aberrations of a gene/geno-
mic segment modulate the expressions/aberrations
on the same locus. In this study the following layer1
models are considered: The karyotype of a chromo-
somal segment affects its copy number variation
(CNV). The CNV, mutation and DNA methylation
o fag e n ea f f e c ti t se x p r e s s i o n .T h em R N Ae x p r e s -
sion of a gene modulates its protein expression.
2. Layer 2 models: Nonlocal aberrations modulate
the expressions/aberrations on different loci, and the
aberrations and phenotypes are connected
via known mechanisms. In this study the following
layer 2 models are considered: The CNV of a
chromosomal segment affects the expression of a
constituent gene on the segment whose CNV data is
not available. The mRNA expression of a transcrip-
tion factor affects the mRNA expressions of its
known targets.
3. Layer 3 models: Nonlocal aberrations modulate
the expressions/aberrations on different loci, and
some links connecting the aberrations and pheno-
types do not have known mechanistic correspon-
dence. In this study the following layer 3 models are
considered: The CNV of a chromosomal segment is
associated with the expression of a gene on another
chromosomal segment. The mutation or DNA
methylation of a gene is associated with the expres-
sion of another gene.
To explain the expression data of a gene we incre-
mentally incorporate observed aberrations from layer 1
to layer 3 models. Local aberrations on the same locus
are considered first because they can provide a direct
mechanistic explanation for expression changes. Nonlo-
cal aberrations with known mechanistic links to expres-
sions are then introduced since they are consistent with
the known mechanistic models and require few addi-
tional assumptions to fit the data. Indirect associations
with chromosomal segment CNVs, gene mutations, and
DNA methylations are invoked only when the layer 3
models significantly outperform the lower-layered
models.
Data sources and processing
Seven datasets on NCI-60 cell lines were downloaded
from the website of the Genomics and Bioinformatics
Group at NCI [8]: mutation analysis of 24 cancer genes
Figure 1 Three-layered models connecting molecular aberrations and gene expressions. Left: layer 1 models connecting mutations, CNVs,
DNA methylations with mRNA and protein expressions of the same genes (g1 in the diagram). Solid black lines indicate transcription and
translation. Solid green lines indicate layer 1 associations. Associations with mutations or DNA methylations are inhibitory. Middle: layer 2 models
connecting internal segment CNVs and transcription factor expressions with expressions of another gene. Here g1 is a known target of
transcription factor TF1. Dashed red lines indicate layer 2 associations. Right: layer 3 models connecting external segment CNVs, mutations and
DNA methylations with mRNA expressions of a gene on another chromosomal segement. Dotted blue lines indicate layer 3 associations.
Associations with external DNA methylations are inhibitory, whereas associations with external gene mutations can be positive or negative.
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data of DNA copy number variations [17], spectral kar-
yotyping data [6], cytosine methylation profiling on pro-
moters [18], cDNA microarray data [21] and Affymetrix
transcript profile data [22] of mRNA expressions, and
protein expression profiles [13]. The union of these
datasets probed 14856 genes.
The known targets of 643 human transcription factors
were extracted from the TRANSFAC database [43].
Functional descriptions and chromosome coordinates of
39942 human genes were downloaded from the NCBI
database [44]. 4291 cancer-related genes were extracted
from the OMIM database [45].
To utilize the datasets from diverse sources we
adopted the following normalization procedures. Muta-
tion states were treated as binary random variables and
all other aberrations/responses were treated as discrete
random variables with three possible states - up-regula-
tion, down-regulation and no change. We applied prob-
abilistic quantization to convert the measurement
values into the probabilities of the three possible states.
Briefly, denote zij the observed value of gene i on cell
line j,a n dxij its discrete hidden state. zij was first rank-
transformed into the cumulative distribution function
(CDF) value yij. Families of polynomial quantization
functions fy y ij ij 
 () ≡ and fy y ij ij 
 ()( ) ≡− 1 then con-
verted yij into the probabilities of the hidden state P(xij
=1 | yij, g )a n dP(xij =- 1 | yij, g). Finally P(xij|yij)w a s
obtained by integrating over the parameter g of quanti-
zation functions (Additional file 1, Figure S1). Probabil-
istic quantization preserves the information of
continuous data and makes it accessible for simple dis-
crete models such as logistic regressions and Bayesian
networks. Details of the probabilistic quantization proce-
dures are described in Additional file 1 (Section Data
processing).
The cDNA and Affymetrix expression data intersect in
5251 genes. Intra-gene correlation coefficients are signif-
icantly higher than the background distribution of all
probes between the two datasets (Additional file 1,
Figure S2; the means of the intra-gene correlation coeffi-
cients and the background distribution are 0.4 and 0
respectively, the Komolgorov-Smirnov p-value < 10
-100),
confirming the consistency of cDNA and Affymetrix
data. We then combined the two datasets by selecting
the genes which either had consistent cDNA and Affy-
metrix profiles or were probed in only one dataset.
Overall, the combined dataset contains 8094 gene
expressions (4231 cDNA and 3863 Affymetrix data).
Details of the dataset combination procedures are
described in Additional file 1 (Section Combination of
cDNA and Affymetrix data).
Logistic regression models of molecular aberrations
We used logistic regressions to model the effects of
molecular aberrations on gene expressions. Denote y the
expression of a gene and x the local and nonlocal aber-
rations that affect y. The conditional probability is
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fi(x)’s are scalar feature functions specifying the rela-
tions of x and y. li’s are nonnegative parameters, and
Z(x) is the partition function that normalizes the condi-
tional probabilities. In this work, fi(x)’sa r ed e t e r m i n e d
by explicit assumptions about the effects of molecular
aberrations on gene expressions. f(x)=x if aberration x
activates expression y. f(x)=- x if aberration x represses
expression y. In our study only two types of relations
are repressive: the effects of DNA methylations on gene
(mRNA or protein) expressions and the effects of muta-
tions on the negatively associated gene expressions.
A model contains multiple feature functions if the
combinations of multiple aberrations explain the data.
For instance, if gene expression y is repressed by either
mutation x1 or DNA methylation x2 of the same gene,
then the exponent of equation 1 is -l1x1 - l2x2.
The log likelihood of a logistic regression model has
the following form:
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where Cx and Cy stand for configurations of x and y,
and N(Cx), N(Cx, Cy) the frequencies of their occur-
rences. Probabilities of input variables P(xk) are modeled
as independent multinomial distributions with a uniform
Dirichlet prior. Probabilistic quantization yields frac-
tional counts on each configuration for each sample. On
a specific cell line i the fractional counts of yi = -1, 0, 1
are P(yi =- 1 ) ,P(yi =0 ) ,P(yi = 1) obtained from prob-
abilistic quantization. N(Cx) and N(Cx, Cy) are calculated
by summing the fractional counts of each configuration
over the samples. The maximum likelihood parameters
of li’s are numerically estimated using the Newton-
Raphson method.
Inferring segment CNVs from CGH data
The CGH array data from [17] provides a sparse sam-
pling on the genome-wide CNVs as only 219 genes
contain valid CGH data. However, since events of copy
number changes often cover multiple adjacent loci on
a chromosome, it is possible to extrapolate the CGH
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chromosomal segments. Spatial dependency of CNVs is
manifested from the measurements of 219 genes on a
CGH array [17] and confirmed in Additional file 1,
Figure S3. Most strongly correlated pairs appear in the
adjacent probes of the same chromosomes. Comparison
of the distributions of correlation coefficients of adja-
cent genes versus the entire gene set also supports the
spatial dependency (Komolgorov-Smirnov p-value <
8.44 × 10
-296).
However, not all the genes on the same chromosomes
are highly correlated. Some chromosomes can be parti-
tioned into multiple segments where intra-segment
genes are highly correlated and inter-segment genes are
poorly correlated. We devised a recursive algorithm to
partition each chromosome into correlated segments. In
brief, the CGH data of all probes on the same segment
were treated as instantiations of a common hidden vari-
able (a naive Bayes model, [46]). The algorithm itera-
tively partitions a segment that optimizes the joint
likelihood of the naive Bayes model and stops when
further partitions do not improve the likelihood score.
Detailed procedures of the partitioning algorithm are
described in Additional file 1 (Section Partitioning a
chromosome into segments according to CGH data).
Using this algorithm we partitioned 23 chromosomes
(there are no probes on the Y chromosome) into 49 seg-
ments. Table 1 reports the chromosome coordinates, the
numbers of NCBI genes and CGH probes on each seg-
ment. The correlation coefficients of intra-segmental
probes are substantially higher than those of inter-seg-
mental probes (Additional file 1, Figure S4; mean corre-
lation coefficients 0.65 and 0 respectively, Komolgorov-
Smirnov p-value < 10
-260). Disparity between the two
distributions justifies the accuracy of the partitioning
algorithm.
The CGH data of the probes on the same chromoso-
mal segments were combined to infer the CDF values of
the segment CNV data. We again treated the segment
CNV as a hidden variable of a naive Bayes model and
the CGH data of probes on the segment as instantia-
tions of the hidden variable. For each sample i,t h el o g
likelihood of the model is
Lx Px Py x ii i
j
ij i (, ) l o g() l o g ( |) . y =+ ∑ (3)
where xi is the hidden segment CNV on sample i and
yi the observed CGH data on sample i. yi is indexed by
probe j on the segment. By substituting xi =0 ,± 1i n t o
equation 3 we obtain the unnormalized posterior prob-
ability P(xi|yi):
Px x e ii
Lx x ii (| ) .
(, ) =∝
= y
y (4)
T h eC D Fv a l u eo fxi is obtained by applying the
inverse function of probabilistic quantization to P(xi =
x|yi).
Model selection
To identify the molecular aberrations explaining a gene
expression data, we incrementally augmented the model
by launching a series of hypothesis tests. A new variable
is included in the model if the augmented model signifi-
cantly outperforms the old model in fitting the data.
Molecular aberrations are prioritized according to the
layered model classifications. The following model selec-
tion procedures were applied to each gene expression
data.
1. Initially set the null model M1 = M0 to be inde-
pendent; i.e., no aberration explains the data. Evalu-
ate the log likelihood ˆ L0 of the independent model
using a multinomial distribution.
2. Iteratively execute the model augmentation func-
tion augment(M1):
( a )S e l e c ta na b e r r a t i o nv a r i a b l ex according to
the layered modeling framework priority. Create
M2 ⊃ M1 by augmenting M1 with a link connect-
ing x to the expression data y. Also create
′ ⊃ MM 10 by adding the (x, y)l i n kt ot h ei n d e -
pendent model M0. M2 is the joint model of
using M1 and x together to explain y. ′ M1 is the
model of using x alone to fit y.
(b) Estimate the maximum likelihood parameters
of the logistic regression models of M1, ′ M1 and
M2.
(c) Substitute the maximum likelihood para-
meters into equation 2 to calculate the log likeli-
hood values ˆ L1 , ˆ′ L1 and L
^
2 .
(d) Perform three hypothesis tests:
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The p-value of a log likelihood ratio is the maxi-
mum of the p-values obtained by both c
2
approximation and random permutations of the
input vectors of the models. Calculate the
p-values p21, p21’ and p1’0 for the three tests.
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Page 5 of 18Table 1 Location and functional information of chromosome segments. N1: # associated intra-segmented genes,
N2: # associated inter-segment genes
index location length(Mb) # genes # CGH probes amplified tissues N1 N2
1 chr1p 31.00-36.20 49.39 549 7 CNS leukemia 143 28
2 chr1p 13.00-33.00 47.14 253 6 CNS 59 79
3 chr1q 21.00-23.00 6.97 282 2 - 0 0
4 chr1q 23.00-43.00 76.99 419 8 CNS lung 76 20
5 chr2p 12.00-24.10 59.28 406 7 melanoma lung 82 36
6 chr2q 23.00-24.00 7.39 542 2 - 23 11
7 chr3p 24.20-25.00 11.83 118 2 - 18 19
8 chr3p 14.30-21.30 4.08 235 4 - 50 59
9 chr3p 13.00-14.20 11.29 71 2 melanoma 11 130
10 chr3q 13.30-28.00 73.57 375 11 - 81 78
11 chr4p 16.30-16.30 1.17 182 2 - 29 119
12 chr4q 21.00-31.21 56.74 256 6 - 0 0
13 chr4q 31.00-35.10 39.39 110 2 - 0 0
14 chr5q 35.10-35.10 1.64 130 2 lung ovary 20 18
15 chr5q 31.00-31.10 4.22 514 2 - 38 9
16 chr6p 21.20-21.30 11.05 554 3 - 87 49
17 chr6q 21.00-27.00 58.79 278 5 leukemia 30 38
18 chr7q 21.00-22.00 4.07 318 3 - 16 19
19 chr7q 21.00-31.00 23.80 347 3 - 40 19
20 chr8p 11.00-22.00 30.75 182 3 - 36 10
21 chr8q 11.00-13.00 0.23 305 2 - 0 0
22 chr9q 22.30-22.30 0.19 312 2 - 13 26
23 chr9q 34.00-34.10 4.22 236 4 - 34 49
24 chr10q 11.20-26.00 80.46 527 4 - 86 95
25 chr11p 15.40-15.50 3.29 84 3 - 17 23
26 chr11p 13.00-15.50 27.17 165 2 - 34 14
27 chr11q 11.00-13.00 2.33 181 2 - 0 0
28 chr11q 21.00-23.20 18.98 213 5 ovary 44 18
29 chr11q 13.00-14.00 0.80 81 2 - 11 47
30 chr11q 13.00-13.00 0.76 141 3 - 2 17
31 chr12q 13.00-13.30 8.77 479 3 - 41 49
32 chr12q 14.30-24.30 35.40 317 4 - 68 27
33 chr13q 12.30-21.20 27.85 253 4 colon 52 49
34 chr14q 11.20-32.32 84.34 470 5 - 150 46
35 chr15q 22.00-26.10 23.92 441 6 - 94 31
36 chr16p 13.10-13.30 13.53 342 2 - 40 35
37 chr16q 22.10-24.30 20.77 285 2 - 41 29
38 chr17p 13.00-13.30 6.57 245 3 - 47 46
39 chr17q 11.20-22.00 3.42 336 4 - 85 24
40 chr17q 22.00-23.20 4.63 284 3 - 32 28
41 chr18p 11.20-11.31 8.89 213 3 - 17 31
42 chr19q 12.00-13.40 21.22 947 5 - 82 15
43 chr20p 13.00-13.00 2.40 75 3 - 23 14
44 chr20p 11.23-13.00 0.71 68 2 - 11 26
45 chr20q 13.00-13.31 10.16 92 7 - 8 6
46 chr20q 11.20-13.20 13.89 160 11 - 9 5
47 chr21q 22.10-22.30 13.33 154 6 leukemia 41 14
48 chr22q 12.20-13.10 9.92 376 3 leukemia melanoma 48 81
49 chr23q 11.20-28.00 80.71 605 2 - 76 12
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, p1’0 and a pre-specified threshold θ. The follow-
ing cases are considered:
– Both p21 and p21’ ≤ θ: M1 ¬ M2.
– p21 ≤ θ, p21’ >θ, and p1’0 ≤ θ: MM 11 ← ′ .
– p21 > θ, p21’ > θ,a n dp1’0 ≤ θ:
MM M 11 1 ←∪ ′ .
– Otherwise: M1 ¬ M1.
In case 1, the joint model M2 is significantly better
than the current model M1 and the additional vari-
able ′ M1,s oM2 replaces M1. In case 2, the expla-
natory power of the additional variable ′ M1 covers
that of the current model M1,s o ′ M1replaces M1.
In case 3, both M1 and ′ M1 significantly fit the
data but the joint model M2 does not outperform
neither of them. So both M1 and ′ M1coexist as
valid explanatory models. The explanatory power
of ′ M1 is covered by M1 in other cases, hence the
additional variable is discarded.
(f) Iteratively incur augment (M1)i ft h e r ea r e
aberration variables remained.
Like other greedy algorithms the inferred associations
depend on the order of including the features in the
analysis. Despite this drawback the following properties
of the association problem justify the feature inclusion
orders of the algorithm. First, the orders of feature addi-
tions are prioritized by their mechanistic information.
Candidates with local or non-local mechanistic evidence
(layer 1 and 2 associations) are preferred to candidates
without mechanistic evidence (layer 3 associations). Sec-
ond, within each layer the ordering of including features
does not follow an explicit rule. However, since the
model selection algorithm can retract a model with
inferior explanatory power and allow multiple coexisting
models, the artifacts generated from a specific model
selection order should be minimized.
Other computational procedures
Detailed procedures of carrying out simulation studies,
identification of putative regulators, identification of the
putative targets of TP53 mutations, clustering the DNA
methylation data, estimation of the false discovery rates,
evaluation of functional enrichment of the inferred
modules are all reported in Additional file 1.
Results
Simulation analysis
The primary merits of the layered models using logistic
regressions are reduction of possible confounding
factors of indirect associations and capacity in capturing
t h ee f f e c t so fm u l t i p l ei n p u t s .T oj u s t i f yt h e s ea d v a n -
tages we generated simulated data of varying gene num-
bers and noise levels and compared the inferred layered
models with the results of two additional methods. Each
gene expression was modulated by one or two of the
following aberrations: local mutation and DNA methyla-
tion, CNV of its chromosome, and the expression of a
master transcription factor on another chromosome (its
targets were not given when learning the models). Nine
combinations of gene numbers (10, 50 and 100 genes)
and noise levels (additive, zero-mean Gaussian noise
with standard deviations 0.2, 0.3 and 1.0) were used to
generate the simulated data. Two other methods were
applied to learn the simulated data: the Bayes Net Tool-
box for Bayesian network structure learning [47] and
k-means clustering on Matlab (k = 4 where accuracy
was optimal). Each of these methods obtained a directed
graph specifying the statistical relations of the aberra-
tions. Accuracy was determined by counting overlapped
edges of the networks of the underlying models and the
graphs derived from the inferred models. We also
applied the module network learning algorithm [48] to
the simulated data of 10 genes but did not show them
since the sensitivity was considerably smaller than the
other three methods. The procedures of data simulation
and model comparison are described in Additional file 1
(Section Simulation studies).
Figure 2 shows the sensitivity and specificity of the
three methods on the datasets with varying gene num-
bers and noise levels. The layered models (blue bars)
achieve near 100% sensitivity and specificity in each
experimental setting. Bayesian networks (cyan bars)
have comparable sensitivity and specificity at low noise
levels and gene numbers. However, sensitivity drops
substantially with respect to increasing noise levels and
moderately with respect to increasing gene numbers.
For instance, sensitivity is 27% in the datasets of 10
genes and high noise level and 58% in the datasets of
100 genes and low noise level. The smaller number of
true positives are likely due to a conservative model
averaging procedure in learning the network structure.
K-means clusters (magenta bars) have stable yet inferior
sensitivity (between 60% and 70%) and specificity
(between 70% and 90%) at each noise level and gene
number setting.
Summary of the inference results
We applied the layered modeling framework to seven
datasets of NCI-60 cell lines, including mutational
states, mRNA and protein expressions, copy number
variations, cytosine methylations, and spectral karyo-
types. Table 2 shows the number of gene expressions
explained by each type of aberration in each layer.
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model selection were 3.0 and 0.1. Overall, 4364 of 8094
mRNA/protein expressions are associated with layered
models. Both internal segment CNVs (segment CNVs
associated with genes on the same segments) and exter-
nal segment CNVs (segment CNVs associated with
genes on different segments) explain the highest number
of gene expressions (2165 and 1547 genes respectively).
DNA methylations and mutations of some cancer-
related genes are also associated with many gene expres-
sions (935 and 392 respectively). In contrast, only a
small fraction of gene expressions are explained by local
Figure 2 Comparison of prediction accuracy on simulated data. Sub-figures demonstrate the inference results with varying noise levels
(horizontal direction, additive zero-mean Gaussian noise with standard deviations 0.2, 0.3 and 1.0) and gene numbers (vertical direction, 10, 50
and 100 genes). Blank colored bars denote the mean sensitivity and striped colored bars denote the mean specificity over 10 experiments in
each setup. Blue bars (LY) denote layered models. Cyan bars (BN) denote Bayesian network learning. Magenta bars (CL) denote k-means
clustering with k =4 .
Table 2 Summary of gene expression data explained by
each type of aberration.
layer aberration # explained genes validation
1 internal CNV 37 coverage 31.9% (37 of 116)
1 internal mutation 3 coverage 50% (3 of 6)
1 internal methylation 15 coverage 7.98% (15 of 188)
1 internal mRNA 46 coverage 68% (46 of 68)
2 internal segment CNV 2165 coverage 26.77% (2165 of 8067)
2 transcription factor 6 coverage 3.87% (6 of 155)
3 external segment CNV 1547 3 TFs examined, 2 verified
3 external mutation 392 1 TF examined and verified
3 external methylation 935 7 TFs examined, 1 verified
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tion factors.
False discovery rates (FDR, [40]) were evaluated for
the associations of each layer and for all the associa-
tions. We adopted the permutation tests described in
[42] as the null model and calculated two types of
FDRs: (1)
expected   false positives according to the null model
 po
#
# s sitive calls from the data ,
(2)
#
#
 false positives in the 99 percentile of the null model
 p positive calls from the data .
Detailed description about the FDR calculations is
reported in Additional file 1, Section Estimation of false
discovery rates. The FDR of the first type among all
association links is 20.34%, and the FDRs among the
links of layer 1, 2 and 3 models are 6.65%, 7.82% and
27.39% respectively. The FDR of the second type among
all association links is 27.29%, and the FDRs among the
links of layer 1, 2 and 3 models are 11.39%, 15.13% and
38.11% respectively. The increasing FDRs over the layers
are sensible, as layer 1 and 2 models are constrained by
known mechanistic links and are thus less likely to be
spurious. Furthermore, the FDRs calculated from the
expected number of false positives are lower than those
calculated from the 99 percentile of the null distribu-
tions. This is also sensible since the latter gives a much
more conservative estimate of the false positive num-
bers. In both cases the high FDRs for layer 3 associa-
tions indicate the need for additional evidence to verify
these links.
Quantities pertaining to the accuracy of the associa-
tion outcomes - false positive and false negative rates
from the empirical data - are much more difficult to
acquire due to incomplete and sporadic knowledge
about the relations of gene aberrations. We adopt the
following procedures to gauge the accuracy of the asso-
ciations. All the layer 1 and layer 2 associations possess
mechanistic justifications because layer 1 and layer 2
models are based on known or plausible mechanisms of
gene regulation. However, plausible associations are not
necessarily manifested as they might be interfered by
additional mechanisms. For instance, a protein expres-
sion may not be correlated with its mRNA expression
due to post-transcriptional regulation. For layer 1 and
layer 2 models, we reported the coverage of significant
associations relative to the possible mechanistic links in
Table 2. A high percentage of mRNA-protein expression
pairs possess significant associations (46 of 68). In addi-
tion, a relatively high proportion of gene expressions are
associated with the CNVs on the same loci or chromo-
somal segments (37 of 116 and 2165 of 8067 respec-
tively). In contrast, the coverage of other known
mechanisms is low. For instance, 155 genes are the
known targets of valid transcription factors (genes with
valid expression data), but only 6 of them are associated
with their transcription factor expressions. In addition,
we compared the layer 3 associations of transcription
factors with their putative targets from literature and
reported enrichment outcomes.
To validate the accuracy of layer 3 associations we
solicited the top-ranking associations according to their
likelihood scores and attempted to find supporting evi-
dence from previous studies. We categorize the results
of literature search into 3 classes: (1) Previous studies
p r o v i d ed i r e c te v i d e n c ef o rt h ea s s o c i a t i o n s .F o r
instance, knock-out experiments or ChIP-seq assays
identified the targets of a transcription factor, (2)
Previous studies contain indirect evidence for possible
associations. For instance, two associated genes are co-
expressed in specific tissues of non-NCI-60 datasets, (3)
There is no evidence of associations from pubmed key-
word search. False positives - associations which are
known to be false - are difficult to obtain since negative
results are often not reported.
Additional file 1, Table S1 shows the literature search
results for top associations of layer 3 models. 10 of top
50 associations with external segment CNVs possess
indirect evidence. The genes are either on the same
chromosomes of the segments or are putatively regu-
lated by the genes on the segment. 5 of top 50 associa-
tions with external gene mutations possess direct
evidence, and 16 associations possess indirect evidence.
13 of top 50 associations with external DNA methyla-
tions possess indirect evidence. Biological implications
of several top-ranking associations are elaborated in the
subsequent sections, and detailed description about lit-
erature review is reported in Additional file 1 (Section
Global accuracy validation of inferred associations).
In addition to literature survey we also examined the
functional enrichment of theg e n eg r o u p sa s s o c i a t e d
with each aberration. About half of the gene groups are
enriched with some GO classes or annotated pathways.
The results are reported in Additional file 1, Table S2
(Section Functional enrichment analysis).
Expression data explained by known mechanisms
Associations with local aberrations
2239 gene expressions are explained by local or non-
local aberrations with known mechanisms. 56 mRNA
and 47 protein expressions are explained by local aber-
rations of the same genes. Overall, a small fraction of
gene expressions are explained by layer 1 models. Valid
mutation, CNV and DNA methylation data (for each
gene, less than 5 cell lines have missing values) cover
only 24, 219 and 320 genes respectively. By restricting
to the genes where any of these local aberrations is
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Page 9 of 18probed, 20% of mRNA expressions (56 of 280) are
explained. The low number suggests many mRNA
expressions are modulated by aberrations on other loci.
In contrast, 68% of valid protein expressions (46 of 68)
are positively associated with the mRNA expressions of
the same genes. Consistency of mRNA and protein
expression data is prominent when comparing the intra-
gene correlation coefficients with the all-versus-all
correlation coefficients between the two datasets (Addi-
tional file 1, Figure S5; Komolgorov-Smirnov p-value <
1.26 × 10
-27). The results corroborate the quality of
mRNA and protein expression data.
Some gene expressions are explained by the models
with composite (multiple) aberrations. In this case the
expression level of a gene depends on the combination
of multiple local aberrations. Two examples of compo-
site models are shown in Figure 3. The protein expres-
sion of the tumor suppressor CDKN2A (TP16) is
repressed by either frame-shift mutations or DNA
methylations of the gene. Cell lines carrying either one
of these aberrations have low expression levels, whereas
cell lines without these aberrations tend to have high
expression values. Similarly, the mRNA expression of
the oncogene CCND1 (cyclin D1) is associated with
both CNV and DNA methylation. Samples with high
copy numbers and without DNA methylation have over-
all high expression levels, whereas samples with either
low copy numbers or DNA methylation tend to be
down-regulated.
Previous studies indicate that DNA copy numbers of
some genes modulate their expression levels [10]. Posi-
tive associations with CNVs constitute the bulk of layer
1 models explaining mRNA expressions. Among the 116
genes where both CNVs and mRNA expressions are
probed, 37 mRNA expressions are associated with the
local CNVs (coverage rate 31.9%). Top genes with
strong CNV-mRNA associations include NRAS (log
likelihood ratio 12.74, p-value < 10
-4), APEX (log likeli-
hood ratio 12.36, p-value < 3 × 10
-4), NFKB2 (log likeli-
hood ratio 12.32, p-value < 0.0012), RAF1 (log
likelihood ratio 12.17, p-value < 10
-6), and CCNA2 (log
likelihood ratio 11.67, p-value < 0.002). The strong asso-
ciations of RAF1, APEX and CCNA2 were reported in a
comparative analysis of the same datasets [17].
DNA methylation on promoters alters the chromatin
structure surrounding the transcription start sites and
silences gene expressions ([5,11]). In NCI-60 fewer
mRNA expressions are negatively associated with DNA
methylations on their promoters. Among the 188 genes
where both DNA methylations and mRNA expressions
are probed, only 15 have significant associations (cover-
age rate 7.98%). Two top genes with strong methylation-
expression associations are PAX8 (log likelihood ratio
11.28, p-value < 0.0025) and SMO (log likelihood ratio
10.56, p-value < 0.001).
Mutations on a gene may enhance, repress or have no
effect on its function [49]. However, frame-shift inser-
tions/deletions will disrupt reading frames and reduce
expressions. Among the 6 genes where mutations occur
Figure 3 Two gene expressions explained by composite aberrations. Left: CDKN2A protein expressions are repressed by either frame-shift
deletions or DNA methylation. Right: CCND1 mRNA expressions are activated by high copy numbers and repressed by DNA methylation.
WT: wild type, FS: frame shift mutation, CNV: copy number variation.
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ciations of frame-shift mutations and expressions on
tumor suppressors TP53 (log likelihood ratio 8.28,
p-value < 0.05), CDKN2A (log likelihood ratio 5.43,
p-value < 10
-3) and PTEN (log likelihood ratio 10.75,
p-value < 3 × 10
-4). The coverage rate is 50%. In con-
trast, there is no apparent association of point mutations
and gene expressions.
Cis-regulatory associations with segment CNVs
Most expressions are not associated with local aberra-
tions of the same genes due to the sparseness of the
aberration data and possible trans-regulation of genes
on other loci. Layer 2 models associate non-local aberra-
tions and gene expressions with known mechanistic
links. In this study two types of layer 2 associations are
considered: associations of chromosomal segment CNVs
with the expressions of their constituent genes, and
associations of the expressions of transcription factors
and their known targets. Overall, internal segment
CNVs explain a large number of gene expressions,
whereas only a few associations of transcription factors
with their known targets are found.
The expressions of 2165 genes are associated with
their segment CNVs (coverage rate 26.77%). Table 1
reports the number of intra-segment genes associated
with each segment CNV. The number of genes
explained by internal segment CNVs is evidently pro-
portional to the gene density and length of the segments
(correlation coefficients 0.66 and 0.58 respectively).
In NCI-60 11 chromosomal segments have tissue-speci-
fic CNV profiles (Table 1 and Additional file 1, Figure S6).
These segment CNVs are associated with many tissue-spe-
cific expressions of their constituent genes, suggesting that
some tissue-specific expressions may arise from the copy
number changes of the chromosomal segments. For
instance, segment 2 (chromosome 1p 13-33) is amplified
in the Central Nervous System (CNS) cell lines, and the
associated genes are enriched in the GO category of neural
development. Segment 9 (chromosome 3p 13-14.20) is
amplified in melanoma, and the associated genes are
enriched in the GO category of transporter activity.
Tumor phenotypes arising from the copy number
changes of oncogenes or tumor suppressors are reported
[10]. We extracted 4291 cancer-related genes from the
OMIM database (OMIM) and identified 452 cancer-
related genes associated with the CNVs on their chro-
mosome segments. The results are reported in Addition
file 1, Table S3.
Trans-regulatory associations with transcription factor
expressions
Besides the cis-regulation of segment CNVs on their con-
stituent gene expressions, transcription factors may regu-
late their targets on other chromosomes. To identify
these trans-regulatory relations we extracted the known
targets of 643 transcription factors from the TRANSFAC
database [43] and associated the mRNA expressions of
each transcription factor with its targets. The known tar-
gets in TRANSFAC are likely to be under-estimated, as
only 10 transcription factors have valid expression data
and contain more than 10 targets with valid expression
data. Overall there are 155 transcription factor-known
target pairs. Among them two transcription factors have
significant associations with some of their known targets.
MITF expression is associated with 4 of 9 targets: TYR,
DCT, MLANA and TYRP1, and MYC expression is asso-
ciated with 2 of 12 targets: CXCR4 and YBX1. The cover-
age rate is 3.87%.
Associations of CGH and karyotype data
To examine the effects of large-scale karyotype aberra-
tions on DNA copy numbers we compared the segment
CNVs inferred from the CGH data with the spectral kar-
yotyping (SKY) data of NCI-60 cell lines [6]. Overall,
copy numbers of the 49 chromosome segments derived
from SKY and CGH data exhibit moderate correlations
(Additional file 1, Figure S7). The means of intra-seg-
ment and all-vs-all correlation coefficients are 0.23 and 0
respectively (the Komolgorov-Smirnov p-value < 2 ×
10
-19). 14 of 49 segments have significant associations
between the two datasets (log likelihood ratio ≥ 4.0,
p-value ≤ 0.05). The two datasets are more strongly cor-
related when segments have extreme copy numbers.
About one quarter of the data points have low (≤ 0.1) or
high (≥ 0.9) normalized CGH values (793 and 718 of
2940 respectively). About half of the data points with ≤ 1
copy according to SKY also have low CGH values (100 of
224), whereas about one third of the data points with ≥3
copies according to SKY also have high CGH values (536
of 1623). The stronger correlation between SKY and
CGH data on low copy number data points might result
from the asymmetric influence of large-scale karyotype
aberrations on copy numbers: deletions of a chromosome
eradicate its DNA copies, while duplications do not
necessarily increase the copy numbers if structural aber-
rations occur on the duplicated chromosomes.
The SKY data in NCI-60 provides lower resolution
information about copy number variations than the
CGH arrays, as only the cytogenetic bands of the abnor-
mal karyotypes were reported. Therefore, we expected
the segment CNVs derived from the SKY data would be
less powerful to fit the gene expression data. Indeed, the
segment CNVs derived from the SKY data invoked
fewer associations than the CGH data: 1395 and 1526
gene expressions were associated with intra and internal
segment CNVs derived from the SKY data, whereas
2165 and 1547 intra and inter segment associations with
the CGH data were found.
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Many gene expressions are not explained by layer 1 or 2
models due to the incomplete information of the simple
mechanisms listed above. Layer 3 models include the
associations not constrained by known mechanistic
links. In this study we considered the following types of
layer 3 associations linking gene expressions with each
type of molecular aberrations: segment CNVs on other
chromosomes, mutations and DNA methylations of can-
cer-related genes obtained from OMIM. Overall, asso-
ciations with external segment CNVs, mutations and
DNA methylations explain a large number of expression
data.
Associations with external segment CNVs
The expressions of 1547 genes are associated with the
CNVs on other chromsomal segments. Table 1 reports
the number of genes associated with each external seg-
ment CNV. Unlike internal segment CNVs, the number
of genes associated with external segment CNVs is
uncorrelated with the gene density and length of the
segments (correlation coefficients 0.05 and 0.19 respec-
tively). Some short segments accommodate a small
number of genes but are associated with many genes on
other loci. For instance, segment 11 (chromosome 4p
16.3) is only 1.17 Mb long but is associated with 119
external gene expressions.
It is difficult to directly validate the accuracy of asso-
ciations with external segment CNVs as many possible
mechanisms may underlie these associations. We con-
sidered one simple mechanism: copy number variations
alter the expressions of a regulator gene on the segment,
which modulates the expressions of its downstream
genes on other segments. We identified these putative
regulators based on the following criteria: (1) they are
transcription factors, (2) they are related to cancer
according to the OMIM database, (3) their expressions
are explained by internal segment CNVs, (4) their
expressions are associated with more than 20 genes on
other chromosomes (see Additional file 1, Section Iden-
tification of master regulators, for the filtering proce-
dure). 7 putative regulators were identified and reported
in Table 3. Among them MITF, MYB and E2F3 contain
information of downstream targets, and the association
outcomes of MITF and MYB conform with the prior
information.
MITF encodes a transcription factor that regulates the
differentiation and development of melanocytes and pig-
ment cell-specific transcription of the melanogenesis
enzyme genes [50]. It is located on segment 9 (chromo-
some 3p 13-14.2). Both segment 9 CNV and MITF
mRNA expression undergo melanoma-specific amplifi-
cation. Moreover, MITF expression is associated with
the 246 melanoma-specific gene expressions. This num-
ber far exceeds the 9 MITF targets from TRANSFAC.
To gather a more complete information of MITF targets
we extracted 106 experimentally validated MITF targets
from [51] and found they intersected with our MITF-
associated genes on 41 genes (hyper-geometric p-value
< 5.1 × 10
-46). Indeed, the causal chain from the amplifi-
cation of chromosome 3p to the disregulation of MITF
and its targets in NCI-60 was previously reported [31].
The upper left panel of Figure 4 shows the CNV of seg-
ment 9 and expressions of MITF and its associated
genes.
MYB (c-myb) is a transcription factor involved in cell
cycle progression, cell proliferation and differentiation in
hematopoiesis [52]. It is located on segment 17 (chr6q
21-27). Amplifications of this oncogene cause its abnor-
mal expressions in leukemia and other solid tumors
([52,53]). In NCI-60 both segment 17 CNV and MYB
mRNA expression are elevated in leukemia cell lines.
Thus MYB may mediate the associations of segment 17
with 141 leukemia-specific genes on other chromo-
somes. The lower left panel of Figure 4 shows the seg-
ment 17 CNV and expressions of MYB and its
associated genes.
To further validate the associations with MYB we
examined the mRNA expression data of NCI-60 cell
lines exposed under radiation [54] and an expression
data of 73 normal tissues [55]. 64 genes are associated
with MYB expressions under the unperturbed condition
and are probed in the radiation dataset. Among them 26
are also associated with MYB expressions in the radia-
tion dataset (see Additional file 1, Section Validation of
master regulator-associated genes on the radiation data,
for the verification screening procedure). Conservation
of MYB-associations between the two datasets is signifi-
cant (hyper-geometric p-value ≤ 0.0024). Moreover, in
an expression dataset of 73 normal tissues MYB and 20
of these 26 genes are highly expressed in blood and
Table 3 Putative transcription factor mediating inter-segment CNV associations. N: # genes on other chromosomes
correlated with the putative regulator
gene desc segment N gene desc segment N
MITF microphthalmia-associated TF seg 9 246 MYB v-myb myeloblastosis viral oncogene seg 17 141
TCF7L2 TF7-like 2 (T-cell specific, HMG-box) seg 24 101 E2F3 E2Ftranscription factor 3 seg 16 78
ZNF148 zinc finger protein 148 seg 10 69 GTF3A general transcription factor IIIA seg 33 69
MLF1 myeloid leukemia factor 1 seg 10 50
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Page 12 of 18bone marrow samples. These lines of evidence suggest
that the MYB-associated genes are either downstream
targets or co-regulated partners of MYB. The right
panel of Figure 4 shows the expression data of the MYB
module under unperturbed and radiation conditions.
E2F3 is a member of the E2F transcription factor
family that is over-expressed in bladder and prostate
cancers [56]. We extracted 82 putative targets of E2F3
from knock-down experiments in bladder cancer [56]
and found no overlap with the 78 E2F3 associated genes
in NCI-60.
Associations with external gene mutations
We considered the associations of gene mutations and
expressions in both directions: the mutation of one gene
co-occurs with the up-regulation (positive) or down-reg-
ulation (negative) of another gene. Among the 24
mutated genes 6 are selected as they are mutated in
more than 10 cell lines. Overall, 392 gene expressions
are significantly associated with at least one of the 6
gene mutations in either direction. The left panel of
Table 4 reports the number of gene expressions asso-
ciated with each gene mutation. CDKN2A and TP53
mutations are associated with the highest numbers of
gene expressions in both directions (78 positive and 70
negative associations for CDKN2A, 43 positive and 49
negative associations for TP53).
Only one mutated gene (TP53) is a transcription fac-
tor and has information about downstream targets. To
validate the association results we extracted 45 known
TP53-responsive genes confirmed by ChIP-Seq assays
[57] and compared them to the genes positively and
negatively associated with TP53 mutations. The 49
genes negatively associated with TP53 mutations have a
significant enrichment with the 45 TP53 targets
Table 4 Associations with gene mutations
mutated gene N1 N2 gene logratio pvalue
CDKN2A 78 70 *MDM2 3.156 1.790e-02
TP53 43 49 *FDXR 3.065 <1.000e-04
PIK3CA 49 12 *HSPB8 3.000 1.770e-02
PTEN 25 20 *THBS2 2.901 6.140e-02
KRAS 13 13 *CDKN1A 2.350 1.400e-03
APC 14 8 *TNFRSF10B 2.348 3.700e-03
LTBR 2.296 <1.000e-04
EGFL7 2.163 1.500e-03
*BAX 2.154 9.900e-03
TMEM5 2.008 1.400e-03
Columns 1-3: number of gene expressions associated with each gene
mutation in either direction. N1: # positively associated genes, N2: # negatively
associated genes. Columns 4-6: top gene expressions negatively associated
with TP53 mutation. Genes marked by asterisks are known TP53-regulated
targets.
Figure 4 T w oe x a m p l e so fc i sa n dt r a n sa c t i n ge f f e c t so fC N V so ng e n ee x p r e s s i o n s . Left: Two modules are associated with putative
regulators and external segment CNVs. The upper half of the heatmap shows the CNV of segment 9 (chr3p 13-14.2), the expression of MITF
(chr3p 14.1) and associated genes on other chromosomes. The module is expressed in melanoma cell lines (ME). The lower half of the heatmap
shows the CNV of segment 17 (chr6q 21-27), the expressions of MYB (chr6q 22) and associated genes on other chromosomes. The module is
expressed in leukemia cell lines (LE). Right: mRNA expressions of the MYB module under unperturbed and radiation conditions. The upper half of
the heatmap shows the CNV of segment 17, expressions of MYB and associated genes under the unperturbed condition. The lower half of the
heatmap shows the expressions of MYB and associated genes under radiation.
Yeang BMC Bioinformatics 2010, 11:495
http://www.biomedcentral.com/1471-2105/11/495
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3.32×10
-12). Furthermore, 7 of the top 10 negative asso-
ciations (sorted by log likelihood ratios) are known
TP53 targets. For instance, the top candidate, MDM2, is
a ubiquitin ligase and transcriptional target of TP53
[58]. The right panel of Table 4 reports these top-rank-
ing negative associations with TP53 mutations. In con-
trast, genes positively associated with TP53 mutations
are not enriched with known TP53 targets. Since the
majority of TP53 mutations are loss-of-function (frame-
shift) mutations, our analysis indicates the effects of
TP53 mutations on its activating targets are much more
prominent.
Associations with external DNA methylation
We considered the negative associations of gene expres-
sions with the DNA methylations of 125 signaling pro-
teins or transcription factors. Some genes have similar
methylation patterns, thus their associated expressions
are highly overlapped. We obtained 14 clusters of
methylated genes according to their associated expres-
sions (see Additional file 1, Section Clustering the DNA
methylation data). Additional file 1, Table S4 sum-
marizes the information of these clusters.
Most of these clusters are associated with tissue-speci-
fic expression patterns. The left panel of Figure 5 shows
the methylation and expression data of the top 2 clus-
ters. Cluster 1 contains the highest number of methy-
lated genes (16). These genes are hyper-methylated in
colon cancer and leukemia cell lines and hypo-methy-
lated in CNS and melanoma cell lines. They are nega-
tively associated with 490 genes. Methylated genes in
cluster 1 include proteins highly expressed in neural sys-
tems (CHGA, GABRB3, GAS7, FEV), strongly related to
leukemia (TCL1A, FLT3, FLT4), involved in cell growth
and proliferation (EGFR, WT1, SMO, IGF2, RET), and
transcription factors involved in diverse or unknown
functions (PAX3, PAX7, HOXC13, ZIM2). Cluster 2
contains 2 methylated genes BCR and BCL7A. They are
hyper-methylated in CNS and melanoma samples and
hypo-methylated in colon and leukemia samples. They
are negatively associated with 157 genes.
7 methylated genes are associated with more than 40
gene expressions: ZIM2, PAX8, PAX7, PAX3, BCR,
TCL1A, BCL7A. The right panel of Figure 5 shows the
methylation patterns of 3 PAX genes and their asso-
ciated expressions. Among them the expression profiles
of PAX3-associated genes are consistent with its
Figure 5 Trans acting effects of DNA methylations on gene expressions. Left: DNA methylation and gene expression data of the top 2
clusters of external methylation associations. From the top, the heatmap of the rows displays (1)methylation data of 16 genes in cluster 1, the
height of each pixel is amplified ten times, (2)expression data of 490 genes associated with the methylated genes in cluster 1, (3)a black
separator of the two clusters, (4)methylation data of 2 genes in cluster 2, the height of each pixel is amplified ten times, (5)expression data of
157 genes associated with the methylated genes in cluster 2. Right: DNA methylation and gene expression data pertaining to 3 PAX genes.
From the top, the heatmap displays (1)PAX3 methylation data, (2)expression data of 115 genes associated with PAX3 methylation, (3)a black
separator, (4)PAX7 methylation data, (5)expression data of 140 genes associated with PAX7 methylation, (6)a black separator, (7)PAX8 methylation
data, (8)expression data of 83 genes associated with PAX8 methylation. Tissue abbreviations: BR:breast, CNS:central nervous system, CO:colon, LE:
leukemia, ME:melanoma, LC:lung, OV:ovarian, KD:kidney.
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Page 14 of 18function. PAX3 is a regulator of MITF [59] and is
involved in melanocyte-specific gene expressions
([60,61]). Thus in addition to amplification of segment 9
CNV the hypo-methylation of PAX3 in melanoma may
also up-regulate the melanoma-specific gene
expressions.
Tissue-specific patterns of gene expressions and other
aberrations
Due to their distinct origins from 9 tissue types, NCI-60
cell lines exhibit heterogeneous patterns of pathway/
gene activities and molecular aberrations. In principle,
associations between molecular aberrations and gene
expressions may persist in multiple tissue types. For
instance, TP53 mutations and the associations with its
putative targets occur in most tissue types. However, to
understand the mechanisms underlying each tumor type
it is of interest to identify the tissue-specific patterns of
molecular aberrations, gene expressions, and their
associations.
We identified the tissue-specific patterns of 8094 gene
expressions and sorted these patterns by the numbers of
their constituent genes. For each pattern we then identi-
fied the dominant associations and enriched pathways
and GO categories of the constituent genes. Detailed
description of the identification of tissue-specific pat-
terns is reported in Additional file 1, Section Identifying
tissue-specific patterns of gene expressions. Table 5 lists
the information of the top-ranking tissue-specific pat-
terns. The first pattern contains 682 genes expressed in
leukemia. Enrichment with generic processes of DNA
replication, transcription, splicing and cell cycle indi-
cates high activities of cell division and growth in leuke-
mia cell lines. Many genes are associated with segment
17 (chr6q 21-27) CNV. From previous discussions some
of these associations are likely to be mediated by MYB
expressions. The second pattern contains 465 genes
expressed in melanoma and are enriched with processes
of melanosome, transporters and glycogen metabolism.
Genes involved in melanocite differentiation are defi-
nitely expressed in melanoma. In addition, high activities
of transport genes such as ABC transporters may
account for strong drug resistance of melanoma cell
lines (by analyzing the data from [23], results not
shown). Dominant associations are the CNVs of seg-
ments 9 (chr3p 13-14.2) and 10 (chr3q 13.3-28) and
PAX3 methylation. From previous discussions the asso-
ciations with segment 9 CNV and PAX3 methylation
are likely mediated by MITF expressions. Some enriched
biological processes of the remaining patterns are con-
sistent with the features of the corresponding tissues.
Enrichment in cell cycle, DNA replication and transla-
tion genes reflects the high growth and division rates of
leukemia and colon epithelial cells. Enrichment with
transport and ion binding genes in kidneys and enrich-
ment with estrogen receptors in ovarians are consistent
with their tissue functions. However, some patterns do
not possess prominent associations with observed aber-
rations, and other patterns lack putative regulators med-
iating the associations between segment CNVs and gene
expressions.
Discussion
It is difficult to systematically evaluate the accuracy of
the association outcomes since the mechanisms con-
necting molecular aberrations and gene expressions
remain largely unknown. In this study we applied sev-
eral procedures to validate the predictions. First, simula-
tion studies indicate that high sensitivity and specificity
of the links inferred from the layered models are robust
against noise levels and gene numbers. Second, a con-
servative estimate yields FDRs of layer 1 and 2 models
below 15% and the FDR of layer 3 models to be 38%.
The ostensibly high FDR of layer 3 models is due to the
large number of possible associations and strong depen-
dency of the features in NCI-60 data. However, since
the goal is an explorative analysis of possible links
explaining gene expressions instead of identifying the
features segregating a specific phenotype (e.g., survival
duration), we can apply stringent cutoffs and external
knowledge to trim the spurious associations. Third, the
coverage rates (# association links/# known mechanistic
Table 5 Top tissue-specific patterns of gene expressions and the associated molecular aberrations. CNV: copy number
variation, mut: mutation, meth: DNA methylation.
tissues # genes aberrations functions
leukemia 682 seg 17, 11 CNV nuclear transport, splicing, cell cycle, RNA synthesis, DNA replication
melanoma 465 seg 9, 10 CNV, PAX3 meth. glycogen metabolism, melanosome, transporter
colon 402 seg 33 CNV, APC TP16 mut. liver development, cell cycle
CNS 334 seg 2, 49 CNV -
kidney 251 - apoptosis, transport, ion binding, cell shape
colon, leukemia 198 seg 11 and 33 CNV DNA replication, translation
breast 147 seg 16 CNV endoplasmic reticulum
ovarian 106 - estrogen receptor
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Page 15 of 18links) in layer 1 and 2 models vary considerably by types
of association links. The heterogeneous coverage rates
reflect the diverse characteristics of the mechanisms.
For instance, frame-shift mutations almost certainly dis-
rupt mRNA synthesis hence yield strong associations
with gene expressions. In contrast, the association of a
transcription factor-target pair may be weak since their
regulatory interaction is present in only certain cell
types. Fourth, top-ranking layer 3 associations with sin-
gle genes (mutations, methylations) possess more sup-
porting evidence from previous studies than associations
with chromosomal segments. This is because the major-
ity of previous studies report associations between genes
(e.g., co-expression) rather than associations between
genes and chromosomal segments. Fifth, the inferred
layer 3 models involved in a few transcription factors
with rich information are compared with their known
targets. Among the 3 transcription factors (MITF, MYB,
E2F3) which may mediate the associations from their
segment CNVs to the expressions of other chromo-
somes, associations from two of them (MITF, MYB)
have experimental supports according to previous stu-
dies. Layer 3 associations with mutations of the only
transcription factor (TP53) are also enriched with its
known targets.
Many questions arise from our analysis results and
demand further investigations. It is unclear why some
gene expressions are modulated by the copy numbers of
their local segments but others are not. Other factors
determining transcript levels (e.g., chromatin structure,
protein and DNA modification, trans-regulation by
other transcription factors, RNA degradation) may mask
or dilute the effect of copy numbers. In-depth analysis
on the alterations of gene regulation are required to
investigate the effects from other factors.
Associations in this study are derived from observa-
tional data alone. Causal information is partially
encoded in the mechanistic assumptions of the model
(e.g., mutation of a gene affects its expression, but muta-
tion is not altered by gene expression). Yet perturbation
data such as knock-outs/downs and knock-ins are
required in order to fully discern the causal chains con-
necting certain aberrations. For instance, to validate that
E2F3 mediates the associations from segment 16 CNV
to gene expressions on other chromosomes, we can
knock-down E2F3 and observe the responses of the
putative targets. In addition to validation, the layered
models can also include perturbation data at the infer-
ence stage.
We chose NCI-60 data as a testing stone for the
layered modeling framework since it is one of the most
comprehensive cancer data in terms of the types of
probed features. Despite its rich information NCI-60
data suffers from several limitations. First, it covers cell
lines from diverse origins. Heterogeneous patterns of
gene/pathway disregulation may add difficulty in analyz-
ing the data. Second, NCI-60 data lacks normal tissues
as negative controls. The “abnormal” changes in gene
expressions, copy number variations and DNA methyla-
tions are all relative to other cancer cell lines in the
panel. Therefore, fluctuations of molecular aberrations
and phenotypic responses are more likely to reflect tis-
sue-specific variations than cancer-normal cell differ-
ences. Third, utility of cancer cell lines in studying the
biology of primary/metastasized tumors and drug dis-
covery is still under debate. These intrinsic drawbacks
of NCI-60 cell lines limit their applications in cancer
biology. Nevertheless, the layered modeling framework
can be applied to other comprehensive datasets of pri-
mary tumors with negative controls (e.g., the TCGA
data).
One potential problem of reconstructing the statisti-
cal/causal relations of molecular aberrations in tumor
datasets is the genotypic/phenotypic heterogeneity of
cells. Unlike cell lines, most tumors have heterogeneous
patterns of gene mutations, copy number variations, epi-
genetic modifications and gene expressions over a popu-
lation of cells. It remains a challenge to deconvolve the
data generated from the mixed population.
Conclusion
Diverse molecular aberrations and phenotypic responses
constitute high-dimensional signatures of cancer cells. It
is also important to reconstruct the statistical and causal
relations of the molecular aberrations and phenotypic
responses. In this study we proposed a layered modeling
framework to identify the associations of gene muta-
tions, copy number variations, DNA methylations,
mRNA and protein expressions on NCI-60 cancer cell
lines. We sequentially applied three layers of models
with increasing complexity and uncertainty to fit the
gene expression data. Layer 1 models use local aberra-
tions to explain the expressions on the same loci. Layer
2 models use nonlocal aberrations with known mechan-
istic links to explain the expressions on different loci.
Layer 3 models use nonlocal aberrations with missing
mechanistic links to fit the expressions on different loci.
Sensitivity analysis from simulated data, false discovery
rates, coverage rates relative to known mechanistic links,
literature search, and comparisons with the known tar-
gets of several well-studied transcription factors all ver-
ify the association outcomes from the layered models.
Specifically, our analysis identifies the following promi-
nent associations on NCI-60 data. First, about 70% of
the protein expressions are significantly associated with
their mRNA expressions, substantiating the consistency
of mRNA and protein expression data. Second, several
gene expressions are associated with composite local
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Page 16 of 18aberrations. For instance, the protein expressions of
CDKN2A are repressed by either frame-shift mutations
or DNA methylations. Third, amplification of chromo-
some 6q in leukemia is likely to elevate the expression
of MYB, and the downstream targets of MYB on other
chromosomes are up-regulated accordingly. Fourth,
amplification of chromosome 3p and hypo-methylation
of PAX3 together may elevate MITF expression in mela-
noma, which may up-regulate the downstream targets of
MITF. Fifth, mutations of TP53 are negatively associated
with its direct target genes. The results justify the utility
of the layered models for the incoming flow of large-
scale, integrated cancer genomic data.
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